Morepen Laboratories Limited (MOREPENLAB.NS)
INR 83.7
(-0.46%)
INR 83.7
(-0.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.17 Billion INR | -7.98% |
| 2022 | 560.78 Million INR | -52.48% |
| 2021 | 1.18 Billion INR | 20.21% |
| 2020 | 981.65 Million INR | 166.02% |
| 2019 | 369.01 Million INR | 21.11% |
| 2018 | 304.7 Million INR | 0.21% |
| 2017 | 304.05 Million INR | -0.66% |
| 2016 | 306.08 Million INR | 11.78% |
| 2015 | 273.84 Million INR | 164.32% |
| 2014 | 103.6 Million INR | 220.74% |
| 2013 | 32.3 Million INR | 123.96% |
| 2012 | -134.8 Million INR | 53.21% |
| 2011 | -288.1 Million INR | 30.35% |
| 2010 | -413.65 Million INR | -13.23% |
| 2009 | -365.33 Million INR | 22.81% |
| 2008 | -473.31 Million INR | 18.01% |
| 2007 | -577.27 Million INR | -36.38% |
| 2006 | -423.27 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 458.91 Million INR | 75.45% |
| 2023 Q2 | 291.39 Million INR | 40.13% |
| 2023 Q3 | 461.92 Million INR | 58.52% |
| 2023 Q4 | 85.8 Million INR | -81.43% |
| 2023 Q1 | 207.94 Million INR | 77.69% |
| 2023 FY | 516.03 Million INR | -7.98% |
| 2022 Q4 | 117.02 Million INR | -19.57% |
| 2022 Q3 | 145.5 Million INR | -36.13% |
| 2022 FY | 560.78 Million INR | -52.48% |
| 2022 Q1 | 87.01 Million INR | -36.21% |
| 2022 Q2 | 227.81 Million INR | 161.8% |
| 2021 FY | 1.18 Billion INR | 20.21% |
| 2021 Q2 | 377.4 Million INR | 1.57% |
| 2021 Q3 | 278.83 Million INR | -26.12% |
| 2021 Q1 | 371.58 Million INR | 297.44% |
| 2021 Q4 | 136.41 Million INR | -51.08% |
| 2020 Q2 | 369.11 Million INR | 99.37% |
| 2020 Q1 | 185.13 Million INR | 81.51% |
| 2020 FY | 981.65 Million INR | 166.02% |
| 2020 Q4 | 93.49 Million INR | -59.26% |
| 2020 Q3 | 229.5 Million INR | -37.82% |
| 2019 Q3 | 67.66 Million INR | -29.74% |
| 2019 FY | 369.01 Million INR | 21.11% |
| 2019 Q4 | 102 Million INR | 50.75% |
| 2019 Q1 | 81.08 Million INR | -23.51% |
| 2019 Q2 | 96.29 Million INR | 18.77% |
| 2018 Q4 | 106 Million INR | 50.8% |
| 2018 FY | 304.7 Million INR | 0.21% |
| 2018 Q3 | 70.29 Million INR | 0.87% |
| 2018 Q1 | 30.15 Million INR | -59.58% |
| 2018 Q2 | 69.68 Million INR | 131.08% |
| 2017 Q2 | 115.37 Million INR | 878.82% |
| 2017 FY | 304.05 Million INR | -0.66% |
| 2017 Q3 | 102.12 Million INR | -11.49% |
| 2017 Q4 | 74.61 Million INR | -26.94% |
| 2017 Q1 | 11.78 Million INR | 0.0% |
| 2016 FY | 306.08 Million INR | 11.78% |
| 2015 FY | 273.84 Million INR | 164.32% |
| 2014 FY | 103.6 Million INR | 220.74% |
| 2013 FY | 32.3 Million INR | 123.96% |
| 2012 Q1 | - INR | 0.0% |
| 2012 Q3 | - INR | 0.0% |
| 2012 Q4 | - INR | 0.0% |
| 2012 FY | -134.8 Million INR | 53.21% |
| 2012 Q2 | - INR | 0.0% |
| 2011 FY | -288.1 Million INR | 30.35% |
| 2010 FY | -413.65 Million INR | -13.23% |
| 2009 FY | -365.33 Million INR | 22.81% |
| 2008 FY | -473.31 Million INR | 18.01% |
| 2007 FY | -577.27 Million INR | -36.38% |
| 2006 FY | -423.27 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Sigachi Industries Limited | 1.47 Billion INR | -183.184% |
| Ind-Swift Limited | 1.22 Billion INR | -240.453% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Sakar Healthcare Limited | 495.5 Million INR | -742.337% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 96.006% |
| Innova Captab Limited | 2.53 Billion INR | -64.752% |
| Divi's Laboratories Limited | 18.31 Billion INR | 77.205% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 6.707% |
| Mankind Pharma Limited | 40.86 Billion INR | 89.787% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Wanbury Limited | 1.7 Billion INR | -144.483% |
| Laurus Labs Limited | 3.94 Billion INR | -5.704% |
| Nectar Lifesciences Limited | 3.89 Billion INR | -7.28% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 53.517% |
| Alembic Limited | 767.77 Million INR | -443.63% |
| Hikal Limited | 1.49 Billion INR | -179.335% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 27.514% |
| Neuland Laboratories Limited | 5.31 Billion INR | 21.516% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 44.656% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 35.811% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 15.547% |
| Themis Medicare Limited | 1.3 Billion INR | -220.299% |
| RPG Life Sciences Limited | 2.29 Billion INR | -82.08% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 90.805% |
| Lupin Limited | 27.75 Billion INR | 84.964% |
| Amrutanjan Health Care Limited | 621.02 Million INR | -572.085% |
| Wockhardt Limited | 140 Million INR | -2881.308% |
| Vaishali Pharma Limited | 6.29 Million INR | -66214.442% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -33.43% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -1850.024% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 19.564% |
| FDC Limited | 3.03 Billion INR | -37.58% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 93.837% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1906.167% |
| Eris Lifesciences Limited | 5.18 Billion INR | 19.451% |
| Venus Remedies Limited | 534.65 Million INR | -680.665% |
| ZIM Laboratories Limited | 1.09 Billion INR | -280.091% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -239.06% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -656.692% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 42.233% |
| Shilpa Medicare Limited | 3.76 Billion INR | -10.96% |
| Albert David Limited | 1.33 Billion INR | -212.774% |
| Ajanta Pharma Limited | 19.67 Billion INR | 78.789% |
| Hester Biosciences Limited | 364.77 Million INR | -1044.236% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 9.415% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 208.33% |
| Gufic Biosciences Limited | 2.89 Billion INR | -44.233% |
| Windlas Biotech Limited | 1.29 Billion INR | -221.338% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -49.814% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -147342.16% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -15100.783% |
| Granules India Limited | 6.52 Billion INR | 36.065% |
| Aarti Drugs Limited | 7.14 Billion INR | 41.614% |
| Bal Pharma Limited | 214.56 Million INR | -1845.216% |
| Alkem Laboratories Limited | 19.46 Billion INR | 78.554% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 95.998% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -118.946% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -1656.212% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -20106.386% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Orchid Pharma Limited | 2.36 Billion INR | -76.776% |
| Medico Remedies Limited | 277.11 Million INR | -1406.157% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -107.753% |
| Ipca Laboratories Limited | 29.59 Billion INR | 85.898% |
| Brooks Laboratories Limited | -72.25 Million INR | 5876.769% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -1574.549% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 83.526% |
| NATCO Pharma Limited | 25.96 Billion INR | 83.923% |
| Suven Life Sciences Limited | -1.22 Billion INR | 440.492% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 20.13% |
| Indoco Remedies Limited | 1.52 Billion INR | -173.802% |
| Alpa Laboratories Limited | 61.51 Million INR | -6685.062% |
| Lasa Supergenerics Limited | -458 Million INR | 1011.307% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 201.429% |